This means that Antrocin is a potential anti-cancer drug, as it interacts with BRAF/MEK/PI3K with equally lower Gibbs free energies compared to the standard inhibitors and a short binding distance to the interacting amino acid, indicating its strong binding affinity to this oncogenic signature. This evidence concerns the gene MAP2K7 and cancer.